/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

BELITE BIO INC - ADR Share Price Today: Live Updates & Key Insights

BELITE BIO INC - ADR share price today is $166.28, up -2.42%. The stock opened at $171.06 against the previous close of $173.75, with an intraday high of $172.62 and low of $168.2.

BELITE BIO INC - ADR Share Price Chart

style
pb-0

BELITE BIO INC - ADR

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

BELITE BIO INC - ADR Share Price Performance

$166.28 -0.0242(-2.42%) BLTE at 13 Mar 2026 12:14 PM Biotechnology
Lowest Today 168.2
Highest Today 172.62
Today’s Open 171.06
Prev. Close 173.75
52 Week High 200.00
52 Week Low 49.00
Day’s Range: Low 168.2 High 172.62
52-Week Range: Low 49.00 High 200.00
1 day return -
1 Week return -1.66
1 month return -3.02
3 month return +19.99
6 month return +150.61
1 year return +146.58
3 year return +473.7
5 year return -
10 year return -

BELITE BIO INC - ADR Institutional Holdings

RTW INVESTMENTS, LLC 1.82

RA Capital Management, LLC 1.10

Eventide Asset Management, LLC 0.97

Eventide Healthcare & Life Sciences I 0.97

Deerfield Management Co 0.59

Soleus Capital Management, L.P. 0.53

Marshall Wace Asset Management Ltd 0.48

MEDICAL BioHealth EUR Acc 0.37

HBM Healthcare Investments AG Ord 0.23

Holocene Advisors, LP 0.21

Fred Alger Management, LLC 0.20

Alger Small Cap Focus Composite 0.15

Alger Small Cap Focus I 0.15

Perceptive Advisors LLC 0.13

ADAR1 Capital Management LLC 0.10

apo Medical Opportunities R 0.07

Quadrature Capital Limited 0.06

Millennium Management LLC 0.05

Affinity Asset Advisors, LLC 0.05

JPMorgan Chase & Co 0.05

Woodline Partners LP 0.05

Artia Global Partners LP 0.05

Geode Capital Management, LLC 0.04

Exome Asset Management LLC 0.04

State Street Corp 0.03

State Street® SPDR® Portfolio EM ETF 0.03

BOOTHBAY FUND MANAGEMENT, LLC 0.03

RIM Global Bioscience EUR 0.02

MS INVF Global Endurance Z USD Acc 0.02

Alger LIfe Sciences Innovation Composite 0.02

Morgan Stanley Global Endurance R6 0.02

Fidelity Nasdaq Composite Index 0.02

Alger Health Sciences A 0.01

Fidelity Nasdaq Composite ETF 0.01

State Street® SPDR® S&P® China ETF 0.01

Virtus LifeSci Biotech Clinical Trls ETF 0.01

ActivePassive International Equity ETF 0.00

Parametric Tax-Managed Emerg Mkt I 0.00

Alger Small Cap Growth B 0.00

Alger Small Cap Growth I-2 0.00

BELITE BIO INC - ADR Market Status

Strong Buy: 3

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

BELITE BIO INC - ADR Fundamentals

Market Cap 6835.32 M

PB Ratio 8.8714

PE Ratio 0.0

Enterprise Value 6560.21 M

Total Assets 0.00 M

Volume 190744

BELITE BIO INC - ADR Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY23:-31426000 -31.4M, FY22:-12475000 -12.5M, FY21:-9792000 -9.8M, FY20:-5753000 -5.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-21690000 -21.7M, Q2/2025:-16320000 -16.3M, Q1/2025:-14277000 -14.3M, Q3/2024:-8679000 -8.7M, Q2/2024:-9494000 -9.5M

About BELITE BIO INC - ADR & investment objective

Company Information Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Organisation Biotechnology

Employees 25

Industry Biotechnology

CEO Dr. Yu-Hsin Lin M.B.A., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow